2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Lee S, Shimasaki N, Lim J, Wong A, Yadav K, Yong W, Tan L, Koh L, Poon M, Tan S, Ow S, Bharwani L, Yap Y, Foo M, Coustan-Smith E, Sundar R, Tan L, Chong W, Kumarakulasinghe N, Lieow J, Koe P, Goh B, Campana D. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. Clinical Cancer Research 2020, 26: 4494-4502. PMID: 32522887, DOI: 10.1158/1078-0432.ccr-20-0768.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiopsyBreast NeoplasmsCoculture TechniquesCombined Modality TherapyDose-Response Relationship, DrugFemaleHumansImmunotherapyK562 CellsKiller Cells, NaturalMaleMiddle AgedReceptor, ErbB-2Response Evaluation Criteria in Solid TumorsStomach NeoplasmsTransplantation, AutologousTrastuzumabConceptsAntibody-dependent cell cytotoxicityAutologous NK cellsNK cellsPhase I trialI trialNK cells expressed high levelsNatural killer (NK) cellsActivated autologous NK cellsHER2-positive solid tumorsPhase I dose escalationPeripheral blood NK cellsHER2-positive malignanciesNK cell infusionNK cell therapyBlood NK cellsNK cell expansionIncreased NK cellsPhase II trialPreliminary antitumor activityNK cell activityCells expressing high levelsHER2-positive cancersStable diseasePartial responseII trialDistinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy
Huhn O, Ivarsson M, Gardner L, Hollinshead M, Stinchcombe J, Chen P, Shreeve N, Chazara O, Farrell L, Theorell J, Ghadially H, Parham P, Griffiths G, Horowitz A, Moffett A, Sharkey A, Colucci F. Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy. Nature Communications 2020, 11: 381. PMID: 31959757, PMCID: PMC6971012, DOI: 10.1038/s41467-019-14123-z.Peer-Reviewed Original ResearchConceptsDecidual innate lymphoid cellsKiller-cell immunoglobulin-like receptorsFetal extravillous trophoblastsInnate lymphoid cellsExtravillous trophoblastNK cellsEarly pregnancyLymphoid cellsFunction of innate lymphoid cellsPeripheral blood NK cellsHLA class I ligandsMaternal dendritic cellsBlood NK cellsDecidual NK cellsGranzyme B levelsProliferating NK cellsImmunoglobulin-like receptorsClass I ligandsIncreased chemokine productionDecidual NKHuman deciduaMaternal cellsDendritic cellsPlacental developmentChemokine production
2014
Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis
Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, Griffiths G, Sieni E, Marcenaro S, Micalizzi C, Montin D, Fagioli F, Moretta A, Mingari M, Moretta L, Notarangelo L, Bottino C, Aricò M, Pende D. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. Journal Of Allergy And Clinical Immunology 2014, 134: 1381-1387.e7. PMID: 24985396, PMCID: PMC7611500, DOI: 10.1016/j.jaci.2014.04.043.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDChildChild, PreschoolFemaleHumansInfantIntracellular Signaling Peptides and ProteinsKiller Cells, NaturalLeukocytes, MononuclearLymphohistiocytosis, HemophagocyticLymphoproliferative DisordersMaleMutationReceptors, ImmunologicSignaling Lymphocytic Activation Molecule Associated ProteinSignaling Lymphocytic Activation Molecule FamilyYoung AdultConceptsX-linked lymphoproliferative disease 1Signaling lymphocytic activation molecule-associated proteinSignaling lymphocytic activation molecule-associated protein expressionHemophagocytic lymphohistiocytosisSH2D1A mutationsNatural killerNK cellsSAP expressionPeripheral blood NK cellsMutation analysisRange of healthy controlsBlood NK cellsNK cell levelsImpaired natural killerCohort of patientsEBV-infected cellsDefective killingCellular cytotoxicityHealthy controlsDiagnostic evaluationLife-threateningSH2D1ADisease 1Prompt identificationPatients
2007
Altered Natural Killer Cells in Type 1 Diabetic Patients
Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, Mathis D. Altered Natural Killer Cells in Type 1 Diabetic Patients. Diabetes 2007, 56: 177-185. PMID: 17192480, DOI: 10.2337/db06-0493.Peer-Reviewed Original ResearchConceptsType 1 diabetesBlood NK cellsType 1 diabetic patientsNK cellsNatural killer cellsDiabetic patientsNatural killerControl subjectsReduced activity of NK cellsKiller cellsDecreased expression of NKG2DActivity of NK cellsPatients relative to control subjectsDevelopment of type 1 diabetesHuman type 1 diabetesEarly onset of diabetesExpression of NKG2DType 1 diabetes pathogenesisGamma interferon expressionDuration of diseaseKIR gene haplotypesOnset of diabetesKIR2DS3 geneNOD miceGamma interferon
1989
Hematopoiesis in vitro coexists with natural killer lymphocytes.
Niemeyer C, Sieff C, Smith B, Ault K, Nathan D. Hematopoiesis in vitro coexists with natural killer lymphocytes. Blood 1989, 74: 2376-82. PMID: 2529928, DOI: 10.1182/blood.v74.7.2376.bloodjournal7472376.Peer-Reviewed Original ResearchConceptsBlood NK cellsNatural killerNK cellsInterleukin-2Colony formationMarrow progenitorsInhibition of MyeloidK562 target cellsNatural killer lymphocytesCell populationsCD16 positive lymphocytesMarrow cell populationsPositive lymphocytesHematopoietic progenitor cellsKiller lymphocytesCell ratioProgenitor cell populationsLymphocytesTarget cellsProgenitor cellsCell sorterInhibitionHuman hematopoiesisDisparate findingsCell lineagesHematopoiesis In Vitro Coexists With Natural Killer Lymphocytes
Niemeyer C, Sieff C, Smith B, Ault K, Nathan D. Hematopoiesis In Vitro Coexists With Natural Killer Lymphocytes. Blood 1989, 74: 2376-2382. DOI: 10.1182/blood.v74.7.2376.2376.Peer-Reviewed Original ResearchBlood NK cellsNatural killerNK cellsInterleukin-2Colony formationMarrow progenitorsInhibition of MyeloidK562 target cellsNatural killer lymphocytesCell populationsCD16 positive lymphocytesMarrow cell populationsPositive lymphocytesHematopoietic progenitor cellsKiller lymphocytesCell ratioProgenitor cell populationsLymphocytesTarget cellsProgenitor cellsCell sorterInhibitionHuman hematopoiesisDisparate findingsCell lineages
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply